Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Exxon Mobil Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $300.86 (market cap $8.04B), while Exxon Mobil Corporation trades at $144.25 (market cap $601.39B). The key difference: Exxon Mobil Corporation is far larger — about 74.8× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Exxon Mobil Corporation pays a 2.84% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | XOM | |
|---|---|---|
Market Cap | $8.04B | $601.39B |
Sector | Health | Energy |
52-Week High | $339.75 | $171.52 |
52-Week Low | $241.71 | $105.83 |
Enterprise Value | $7.85B | $640.62B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
ExxonMobil (XOM) trades at $144.51, up 4.1% today, with a bullish technical outlook and strong earnings beats in recent quarters. The stock shows robust profitability with a net income margin of 7.76% and a solid balance sheet, though revenue and net income have declined from 2022 peaks. Recent news highlights Exxon's Permian Basin advantages and potential oil price spikes, supporting positive sentiment.
XOM offers value with a consensus price target of $169.30, implying 17% upside, but faces risks from volatile oil prices and declining profit margins. Institutional buy ratings at 40.74% reflect cautious optimism, while technical indicators suggest near-term resistance at $146. Investors should weigh the strong cash flow and dividend against energy market uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
